NCT00784888已完成不适用
A Non-Interventional Study Evaluating The Effects Of Aromatase Inhibitor Treatment After 2-3 Years Tamoxifen - As Adjuvant Endocrine Therapy - On Quality Of Life And Safety In Endocrine Responsive Early Stage Postmenopausal Breast Cancer Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 344
- 试验地点
- 1
- 主要终点
- To evaluate the quality of life of patients with early stage postmenopausal breast cancer using aromatase inhibitor following 2-3 years of tamoxifen treatment (switch)
研究概览
简要总结
The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.
详细描述
Group of patients using the same aromatase inhibitor
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with endocrine responsive early stage postmenopausal breast cancer. Patients who received tamoxifen for 2-3 years as adjuvant endocrine therapy. Patients who were approved to switch to aromatase inhibitor treatment during the patient recruitment period.
- •Patients who were informed about the study and accepted to participate.
排除标准
- •Patients having a psychological disorder which will prevent their understanding of questionnaires used for evaluation of quality of life and / or patients who are illiterate.
结局指标
主要结局
To evaluate the quality of life of patients with early stage postmenopausal breast cancer using aromatase inhibitor following 2-3 years of tamoxifen treatment (switch)
时间窗: 2 years
次要结局
- To evaluate patients with early stage postmenopausal breast cancer using aromatase inhibitor following 2-3 years of tamoxifen treatment (switch) in terms of side effects(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic PatientsSchizophreniaNCT00999895AstraZeneca574
已完成
不适用
Health-related Quality of Life in Patients on AnticoagulantsAtrial FibrillationNCT03134911Boehringer Ingelheim535
终止
4 期
Crossover Study From Macitentan or Bosentan Over to AmbrisentanPulmonary Arterial HypertensionNCT02885012Medical University of South Carolina3
已完成
不适用
A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT02287610Amgen75
已完成
4 期
Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.Prostate CancerNCT05304169Zodiac Produtos Farmaceuticos S.A.48